PROCEPT BioRobotics Corporation 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Class II Directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Antal Desai

PROCEPT BioRobotics Corporation’s own tally for this item (“Elect Director: Antal Desai”): 28,444,121 for, 8,511,185 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the nominees for director listed in Proposal 1 in the Company's Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 22, 2026 (the "Proxy Statement"), were elected to serve on the Company's board of directors until the Company's 2029 annua…”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 11,365,510 for, 1,227,290 withheld, 39 abstained.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

Description as filed by funds: Election of Class II Directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Frederic Moll, M.D.

PROCEPT BioRobotics Corporation’s own tally for this item (“Elect Director: Frederic Moll, M.D.”): 36,455,610 for, 499,696 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the nominees for director listed in Proposal 1 in the Company's Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 22, 2026 (the "Proxy Statement"), were elected to serve on the Company's board of directors until the Company's 2029 annua…”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 12,465,991 for, 126,847 withheld, 1 abstained.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

Description as filed by funds: Election of Class II Directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Mary Garrett

PROCEPT BioRobotics Corporation’s own tally for this item (“Elect Director: Mary Garrett”): 29,150,610 for, 7,804,696 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the nominees for director listed in Proposal 1 in the Company's Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 22, 2026 (the "Proxy Statement"), were elected to serve on the Company's board of directors until the Company's 2029 annua…”
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 11,308,690 for, 1,284,115 withheld, 34 abstained.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.

PROCEPT BioRobotics Corporation’s own tally for this item (“3. A proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 26,984,867 for, 9,924,704 withheld — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 in the Proxy Statement, a proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, was approved by the following vote:”
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 10,824,567 for, 1,750,166 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 221 managers: 16,662,554 for, 9,376,884 against, 7,503 abstained, 59,750 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.

PROCEPT BioRobotics Corporation’s own tally for this item (“2. A proposal to ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 47,328,539 for, 21,691 withheld — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 in the Proxy Statement, a proposal to ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026, was approved by the following vote:”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 12,592,839 for.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.